Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

venues and earnings

The Group's revenues are partly dependent on the level of reimbursement provided to the Group by governmental reimbursement schemes for pharmaceutical products. Changes to governmental policy or practices could adversely affect the Group's sales, financial condition and results of operations. In addition, the cost of treatment established by health care providers, private health insurers and other organizations, such as health maintenance organizations and managed care organizations are under downward pressure and this, in turn, could impact on the prices at which the Group can sell its products.

The market for pharmaceutical products could be significantly influenced by the following, which could result in lower prices for the Group's products and/or a reduced demand for the Group's products:

    - the ongoing trend toward managed health care, particularly in
      the US;

    - legislative proposals to reform health care and government
      insurance programs in many of the Group's markets; and

    - price controls and non-reimbursement of new and highly priced
      medicines for which the economic and therapeutic rationales are not
      established.

The prices for certain of the Group's products when commercialized, in particular products for the treatment of rare genetic diseases such as REPLAGAL and ELAPRASE, may be high compared to other pharmaceutical products. The Group may encounter particular difficulty in obtaining satisfactory pricing and reimbursement for its products, including those that are likely to have a high annual cost of therapy. The failure to obtain and maintain pricing and reimbursement at satisfactory levels for such products may adversely affect revenues and earnings.

Parallel importation occurs when an importer finds a cheaper price for a product or equivalent product on the world market and imports that product f
'/>"/>

SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, ... peptides that are used solely in scientific experiments, is ... successful years in business, Maxim Peptide, which was created ... launched a new and updated website that now features ... section has been updated with fascinating articles about peptide ...
(Date:7/11/2014)... July 11, 2014 EPFL and ... the appointment of John P. Donoghue . The ... Geneva . The new Wyss ... in Geneva , has named as ... John P. Donoghue , founder of Brown University,s ...
(Date:7/10/2014)... Women in the West African ... additional family planning option. Sayana® Press has the ... levels of the health system and in communities ... used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone acetate)—with the BD ... first of four African countries expected to begin ...
(Date:7/10/2014)... Terascala, the industry leader in ... a former vice president of product management for Flexera ... of marketing. Terascala’s software when combined with leading compute ... highest performance and most reliable solutions for processing big ... channel expansion and broaden its product portfolio. His leadership ...
Breaking Biology Technology:Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3
... Kensey Nash Corporation,(Nasdaq: KNSY ) today announced that ... ended March 31, 2008 at 7:00 A.M. Eastern Time ... CEO, will be hosting a teleconference,discussing the earnings results ... To participate in the teleconference call, dial 1-612-234-9959. ...
... April 10 Amnis Corporation announced today a,major ... software.,IDEAS version 3.0 incorporates greatly expanded analytical capabilities,while ... IDEAS 3.0 provides the user with dozens of ... strengthen morphological,data analysis. The new software also provides ...
... Mass., April 10 Thermo Fisher,Scientific Inc. (NYSE: ... for the first quarter of 2008 before the market ... conference call on the same day at 9:00,a.m. Eastern ... its first quarter financial,performance as well as future expectations. ...
Cached Biology Technology:Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference 2Amnis Announces Release of Powerful New Image Data Analysis Software 2Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 24, 2008 2
(Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
(Date:7/11/2014)... Sweden, have explored two different ways that allow ... to the formation of oxygen molecules in photosynthesis. ... scientific journal Nature Communications . , "The ... catalysts for water oxidation, which are key components ... storage of solar energy in fuels like hydrogen, ...
(Date:7/11/2014)... In addition to the hippocampus, the marginal division ... and memory. What is the impact degree of ... learning and memory function? Yan Yu and his ... China found, using immunofluorescence staining, that substance P ... hippocampus and striatal marginal division of normal rats. ...
Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Molecular snapshots of oxygen formation in photosynthesis 2
... from early hominid to dominant species, is the defining ... To chronicle this epic narrative an internationally renowned team, ... University, presents the Wiley-Blackwell Encyclopedia of Human Evolution, a ... history. Over two volumes and 5000 entries ...
... Boston, MA - Some 25 million people in the United ... diseases characterized by often debilitating pain in the joints. Now ... gel that could spell the future for treating these diseases ... the targeted release of medicine at an affected joint, and ...
... crustaceans called copepods rule the world, at least when ... numerous multi-cellular organisms in the seas, copepods are an ... webs. To understand and predict how copepods respond ... how many new copepods are born, but how many ...
Cached Biology News:Injectable gel could spell relief for arthritis sufferers 2Injectable gel could spell relief for arthritis sufferers 3Death -- not just life -- important link in marine ecosystems 2
Ultra-sensitive, non-radioactive detection of Protein G. Measure Protein G levels quickly and easily....
TRIS-EDTA based buffer prepared from RNase-free water suitable for storage and dilution of siRNA, pH 8, store at 4 C ...
Request Info...
Ultra-sensitive, non-radioactive detection of rat Osteopontin...
Biology Products: